<DOC>
	<DOC>NCT00252135</DOC>
	<brief_summary>This study is a multicenter, prospective, observational cohort study of ~5000 Xolair-treated and ~2500 non-Xolair-treated patients with moderate to severe persistent asthma and a positive skin test or in vitro reactivity to an aeroallergen.</brief_summary>
	<brief_title>A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Signed informed consent document (in the case of a minor, consent must be given by the child's parent or legally authorized representative) â‰¥12 years of age Physician diagnosis of moderate to severe persistent asthma Evidence or history of positive skin test or in vitro reactivity to an aeroallergen Willingness to participate fully for the duration of the study (5 years) For patients in the Xolairtreated cohort, have received at least one dose of Xolair therapy at the time of enrollment Contraindication to Xolair therapy (e.g., patients who experienced a severe hypersensitivity reaction to Xolair) Acute asthma exacerbation within the previous 2 weeks of screening requiring any of the following: initiation of systemic corticosteroids, increased doses of systemic corticosteroids from baseline, doubling of inhaled corticosteroids, emergency room visit, or hospitalization Acute flare of significant systemic disease (e.g., infection, hematologic, renal, hepatic, cardiovascular diseases, or gastrointestinal diseases), or a recent hospitalization because of their disease within the previous 2 months Use of an experimental drug within 30 days prior to study screening Diagnosis of cystic fibrosis For patients in the nonXolairtreated cohort, any prior treatment with Xolair</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Moderate to severe asthma</keyword>
</DOC>